NCT05107076

Brief Summary

  • 2D Echocardiography with color Doppler assessment: It will be done within 24 h after PPCI
  • Peripheral blood samples were obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.
  • Follow up 2D Doppler echocardiography: will be repeated at 40 days of the event.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 25, 2021

Completed
7 days until next milestone

Study Start

First participant enrolled

November 1, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 4, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2023

Completed
Last Updated

November 4, 2021

Status Verified

October 1, 2021

Enrollment Period

1.2 years

First QC Date

October 25, 2021

Last Update Submit

October 25, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Acute effect of PPCI in STEMI patients on diastolic function and Galactin-3 level

    Determine the acute effect of PPCI in STEMI patients on the level of Galectin 3 and diastolic function within 48 hrs of the event.

    48 hrs

Secondary Outcomes (1)

  • Correlation to patients' outcomes especially in those with initial high serum Galactin-3

    40 days

Study Arms (1)

STEMI patients who underwent PPCI

2D Echocardiography with color Doppler assessment will be done within 24 h after PPCI Biochemical measurements: Peripheral blood samples were obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level. Follow up 2D Doppler echocardiography will be repeated at 40 days of the event.

Diagnostic Test: 2D Echocardiography with color Doppler assessment & Galactin-3 level in blood

Interventions

* Measurements will be 1. Pulsed wave (PW) Doppler 2. E (early diastolic)/A (late diastolic) - Using PW Doppler 3. IVRT (isovolumic relaxation time) 4. Deceleration time (DT) - from the peak of E wave to baseline. 5. E/e'- PW tissue Doppler imaging (TDI) 6. Left atrial volume and left atrial volume index (LAVI) * Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.

STEMI patients who underwent PPCI

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients with age \> 18 years who will present in the emergency department within 12 h (hrs) of the onset of ischemic chest pain \& fulfill the diagnostic criteria of acute STEMI as defined by the universal definition of Myocardial Infarction (9) and are eligible for primary PCI will be included in this study.

You may qualify if:

  • All patients of sample size admitted to the cardiology department of Assiut university hospital with:
  • Acute typical chest pain
  • Positive cardiac enzymes.
  • ECG shows ST-segment elevation MI
  • Documented occlusion of CA then treatment by PPCI

You may not qualify if:

  • \. Patients with well-known factors of left ventricular diastolic dysfunctions, including high blood pressure (over 140/90 mmHg), hypertrophic cardiomyopathy, left ventricular hypertrophy, bundle branch block, ventricular fibrillation, ventricular arrhythmia, severe valvular disease, complete heart block, and previous CABG.
  • \. Patients with the end-stage renal disease usually have markedly increased galactin-3 levels 3. Prior use of thrombolytic agents 4. Refusal of PPCI due to social or religious concerns 5. ST elevation on ECG without obvious coronary artery diseases such as acute myocarditis, early repolarization, or Takotsubo cardiomyopathy 6. Atrial fibrillation at the time of echocardiography examination.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine Assiut University

Asyut, Asyut Governorate, Egypt

RECRUITING

Related Publications (2)

  • Karaye KM, Sani MU. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: a cross-sectional study. BMC Cardiovasc Disord. 2008 Jul 22;8:16. doi: 10.1186/1471-2261-8-16.

    PMID: 18644161BACKGROUND
  • McManus DD, Chinali M, Saczynski JS, Gore JM, Yarzebski J, Spencer FA, Lessard D, Goldberg RJ. 30-year trends in heart failure in patients hospitalized with acute myocardial infarction. Am J Cardiol. 2011 Feb 1;107(3):353-9. doi: 10.1016/j.amjcard.2010.09.026.

    PMID: 21256998BACKGROUND

MeSH Terms

Conditions

ST Elevation Myocardial Infarction

Interventions

EchocardiographyBlood Specimen Collection

Condition Hierarchy (Ancestors)

Myocardial InfarctionMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Intervention Hierarchy (Ancestors)

Cardiac Imaging TechniquesDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisUltrasonographyHeart Function TestsDiagnostic Techniques, CardiovascularSpecimen HandlingClinical Laboratory TechniquesPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Hatem Helmy, Professor

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mariam Hanna, Resident

CONTACT

Yousra Ghazally, Lecturer

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Mariam Bady Adly Hanna

Study Record Dates

First Submitted

October 25, 2021

First Posted

November 4, 2021

Study Start

November 1, 2021

Primary Completion

January 1, 2023

Study Completion

May 1, 2023

Last Updated

November 4, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Locations